Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma

Seminars in Oncology

Volumn 42, Issue 1, 2015, Pages 134-143

  Li, Daneng ^a   O'Reilly, Eileen M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGENPANTUCEL L; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CANCER VACCINE; CAPECITABINE; CISPLATIN; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; TERTOMOTIDE; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR VOLUME; ADENOCARCINOMA; ADJUVANT THERAPY; METABOLISM; PANCREATIC NEOPLASMS;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PATIENT SELECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84923454321     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.12.012     Document Type: Review

References (53)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics,. 2014 CA Cancer J Clin 64 2014 9 29
2. G. Garcea, A.R. Dennison, and C.J. Pattenden Survival following curative resection for pancreatic ductal adenocarcinoma. A systemic review of the literature JOP 9 2008 99 132
3. J.M. Winter, M.F. Brennan, and L.H. Tang Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades Ann Surg Oncol 19 2012 169 175
4. M.H. Kalser, and S.S. Ellenber Pancratic cancer. Adjuvant combined radiation and chemotherapy following curative resection Arch Surg 120 1985 899 903
5. J.H. Klinkenbijl, J. Jeekel, and T. Sahmoud AAdjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancras and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group Ann Surg 230 1999 776 782
6. H.G. Smeenk, C.H. J van Eijck, and W.C. Hop Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation. Long-term results of EORTC trial 40891 Ann Surg 246 2007 734 740
7. J.P. Neoptolemos, J.A. Dunn, and D.D. Stocken Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial Lancet 358 2001 1576 1585
8. J.P. Neoptolemos, D.D. Stocken, and H. Friess A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 2004 1200 1210
9. R.A. Abrams, K.D. Lillemoe, and S. Piantadosi Continuing controversy over adjuvant therapy of pancreatic cancer Lancet 358 2001 1565 1566
10. D.B. Evans, K.R. Hess, and P.W. PISters ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancras Ann Surg 236 2002 694
11. M.A. Choti Adjuvant therapy for pancreatic cancer - the debate continues N Engl J Med 350 2004 1249 1251
12. H. Oettle, S. Post, and P. Neuhaus Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 2007 267 277
13. H. Oettle, P. Neuhaus, and A. Hochhaus Adjuvant chemotherapy with gemcitabine and long term outcomes among patients with resected pancreatic cancer. The CONKO-001 randomized trial JAMA 310 2013 1473 1481
14. W.F. Regine, K.A. Winter, and R.A. Abrams Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial JAMA 299 2008 1019 1026
15. R.R. Dalton, M.G. Sarr, and J.A. van Heerden Carcinoma of the body and tail of the pancreas: is curative resection justified? Surgery 111 1992 489 494
16. I.H. Nordback, R.H. Hruban, and J.K. Boitnott Carcinoma of the body and tail of the pancreas Am J Surg 164 1992 26 31
17. R.A. Abrams, K.A. Winter, and W.F. Regine Failure to adhere to protocol specified raditiation therapy guidelines was associated with decreased survival in RTOG 9701 - a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas Int J Radiat Oncol Biol. Phys 82 2 2012 809 816
18. J.P. Neoptolemos, D.D. Stocken, and C. Bassi Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA 304 2010 1073 1081
19. N.B. Merchant, J. Rymer, and E.A. Koehler Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits? J Am Coll Surg 208 2009 829 841
20. M.M. Corsini, R.C. Miller, M.G. Haddock Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005) J Clin Oncol 26 2008 3511 3516
21. J.M. Herman, M.J. Swartz, and C.C. Hsu Analysis of fluoruacil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large prospectively collected database at the Johns Hopkins Hospital J Clin Oncol 26 2008 3503 3510
22. C.C. Hsu, J.M. Herman, and M.M. Corsini Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study Ann Surg Oncol 17 2010 981 990
23. J. Van Laethem, E. Van Cutsem, and P. Hammel Adjuvant chemotherapy alone versus chemoradiation after curative resection for pancreatic cancer: feasibility results of a randomized EORTC/FFCD/GERCOR phase II/III study (40013/22012/0304) J Clin Oncol (Meeting Abstracts) 26 2008 4514
24. J. Van Laethem, P. Hammel, and F. Mornex Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC 40013-22012/FFCD-9203/GERCOR phase II study J Clin Oncol 28 2010 4450 4456
25. W.C. Liao, K.L. Chien, and Y.L. Lin Adjuvant treatments for resected pancreatic adenocarcinoma: a systemic review and network meta-analysis Lancet Oncol 14 2013 1095 1103
26. M.W. Saif, K.N. Syrigos, and N.A. Katirzoglou S-1: a promising new oral fluoropyrimidine derivative Expert Opin Investig Drugs 18 2009 335 348
27. A. Fukutomi, K. Uesaka, and N. Boku JASPAC 01: randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer J Clin Oncol (Meeting Abstracts) 31 2013 4008
28. M.J. Moore, D. Goldstein, and J. Hamm Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 2007 1960 1966
29. M.D. Danese, C. Reyes, and K. Northridge Budget impact model of adding erlotinib to a regimen of gemcitabine for treatment of locally advanced, nonresectable or metastatic pancreatic cancer Clin Ther 30 2008 775 784
30. P. Hammel, F. Huguet, and J.L. Van Laethem Comparison of chemoradiotherapy and chemotherapy in patients with a locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study J Clin Oncol (Meeting abstracts) 31 2013 4003
31. T. Conroy, F. Desseigne, and M. Ychou FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 19 2011 1817 1825
32. D.D. Von Hoff, T.J. Ervin, and A.F. Arena Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT) J Clin Oncol (Meeting Abstracts) 30 2012 LBA148
33. S. Weden, M. Klemp, and I.P. Gladhaug Long term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras Int J Cancer 128 2011 1120 1128
34. G.K. Abou-Alfa, P.B. Champman, and J. Feilchenfeldt Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine Am J Clin Oncol 3 2011 321 325
35. V.E. Shaw, D.J. Naisbitt, and E. Costello Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer Expert Rev Vaccines 9 2010 1007 1016
36. G.W. Middleton, J.W. Valle, and J. Wadsley A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer J Clin Oncol 31 2013 (meeting abstract 4004)
37. E.M. Jaffee, R.H. Hruban, and B. Biedrzycki Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation J Clin Oncol 19 2001 145 156
38. E. Lutz, C.J. Yeo, and K.D. Lillemoe A lethally irradiated allogeneic garanulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation Ann Surg 253 2011 328 335
39. U. Galili, and D.C. LaTemple Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity Immunol Today 18 1997 281 285
40. D.C. LaTemple, J.F. Abrams, and S.Y. Zhang Increased immunogenicity of tumor vaccines complexed with anti-Gal: Studies in knockout mice for alpha 1,3 glactosyltransferase Cancer Res 59 1999 3417 3423
41. J.M. Hardacre, M.F. Mulcahy, and W. Small Addition of algenpantucel-L immunotherapy to standard of care adjuvant therapy for pancreatic cancer J Clin Oncol 30 2012 (meeting abstract 4049)
42. S. Heinrich, B.C. Pestalozzi, and M. Schafer Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head J Clin Oncol 26 2008 2526 2531
43. S. Gillen, T. Schuster, C. Meyer Zum Buschenfelde, H. Freiss, and J. Kleeff Preoperative/neoadjuvant therapy in pancreatic cancer: a systemic review and meta-analysis of response and resection percentages PLoS Med 7 2010 e1000267
44. G.D. Guetz, P. Nicolas, G.Y. Perret, J.F. Morere, and B. Uzzan Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis Eur J Cancer 46 2010 1049 1055
45. H. Haeno, M. Gonen, and M.B. Davis Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies Cell 148 2012 362 375
46. J.W. Valle, D. Palmer, and R. Jackson Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lesions from the ESPAC-3 study J Clin Oncol 32 6 2014 504 512
47. V.L. Damaraju, M.B. Sawyer, J.R. Mackey, J.D. Young, and C.E. Cass Human nucleoside transporters: biomarkers for response to nucleoside drugs Nucleos Nucleot Nucl 5 2009 450 463
48. J.J. Farrell, H. Elsaleh, M. Garcia, R. Lai, A. Ammar, and W.F. Regine Human ENT1 levels predict response to gemcitabine in patients with pancreatic cancer Gastroenterology 136 2009 187 195
49. W. Greenhalf, P. Ghaneh, j.P. Neoptolemos, D.H. Palmer, T.F. Cox, and R.F. Lamb Pancreatic cancer hENT1 expression and survival form gemciatibne in patients from the ESPAC-3 trial J Natl Cancer Inst 106 2014 1 10
50. E. Poplin, H. Wasan, and L. Rolfe Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma and a prospective evaluation of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment J Clin Oncol 2013 31 (meeting abstract 4007)
51. S.B. Fisher, S.H. Patel, and P. Bagci An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma Caner 119 2013 445 453
52. P.C. Mahon, P. Baril, and V. Bhakta S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer Cancer Res 67 2007 6786 6795
53. A.V. Biankin, J.G. Kench, and E.K. Colvin Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer Gastroenterology 137 2009 558 568